Skip to contentSkip to navigation
TwitterLinkedInInstagram
  • Home
  • News
  • Events
  • Contact Us
  • Search this site

NovaBiotics fast-tracks COVID-19 drug | ONE

Site Navigation

  • About ONE
    nav-arrow About ONE
    nav-arrow Transforming our Region Annual Event 2022
    nav-arrow Transformational Leadership and Action
    nav-arrow Who We Are
    nav-arrow Delivery and Impact
    nav-arrow Regional Economy
    nav-arrow ONE Enterprise Fund
  • Transformational Projects
    nav-arrow Transformational Projects
    nav-arrow BioHub
    nav-arrow SeedPod
    nav-arrow ONE Tech Hub
    nav-arrow Seafood Transformation Project
    nav-arrow North East Adventure Tourism
    nav-arrow Gourmet Food Festival
  • Digital Tech
    nav-arrow Digital Tech
    nav-arrow Transformational Leadership and Action
    nav-arrow ONE Tech Hub
    nav-arrow Accelerate Growth
    nav-arrow Digital Catalyst
    nav-arrow Internationalisation and Market Development
    nav-arrow Strategic Partnerships
    nav-arrow EnergyTech
    nav-arrow ONE CodeBase Tech Startup Next Steps
  • Energy
    nav-arrow Energy
    nav-arrow Energy
  • Food, Drink & Agriculture
    nav-arrow Food, Drink & Agriculture
    nav-arrow Transformational Leadership and Action
    nav-arrow SeedPod
    nav-arrow Accelerate Growth
    nav-arrow Transform Food Production
    nav-arrow Internationalisation and Market Development
    nav-arrow Strategic Partnerships
  • Life Sciences
    nav-arrow Life Sciences
    nav-arrow Transformational Leadership and Action
    nav-arrow BioHub
    nav-arrow Accelerate Growth
    nav-arrow Digital Catalyst
    nav-arrow Internationalisation and Market Development
    nav-arrow Strategic Partnerships
  • Tourism
    nav-arrow Tourism
    nav-arrow Transformational Leadership and Action
    nav-arrow VisitAberdeenshire
    nav-arrow Accelerate Growth
    nav-arrow Gourmet Food Festival
    nav-arrow North East Adventure Tourism
  • Home
  • News
  • Events
  • Contact Us
News
Life Sciences
Posted: 14 May 2020
NovaBiotics fast-tracks drug for COVID-19

North east Scotland’s proven life sciences strength in the development of novel biotherapeutics is being applied to the challenge of the COVID-19 pandemic.

NovaBiotics, the Aberdeen-based clinical stage antimicrobials drug discovery company, has announced the rapid repurposing of its experimental drug Nylexa for the ‘hidden killer’ underlying COVID-19: secondary bacterial lung infections.

The active ingredient of Nylexa is already in advanced clinical trials. It has proven to be safe and effective in clinical studies carried out across the UK, Italy and the US for the complex bacterial lung infections associated with cystic fibrosis. Nylexa could be rapidly re-positioned as a COVID-19 therapy and tested in patients in the second half of 2020.

Nylexa works to boost the body’s ability to fight infection and modulates the immune response to pathogen challenge. Nylexa also ‘supercharges’ antibiotics, boosting their efficacy against difficult to treat and even drug resistant bacteria. More than 50% of the COVID-19 patients who died in Hubei province, China, succumbed to a bacterial infection/sepsis, despite having been given antibiotic therapy. Secondary bacterial pneumonia is such as risk to clinical outcomes of COVID-19 that patients are started on antibiotic therapy to prevent this as soon as they are hospitalised. This increased use of antibiotics will undoubtedly exacerbate antibiotic resistance in the near future.

Deborah O’Neil, CEO of NovaBiotics commented: “A vaccine for COVID-19 is not certain and we must look to develop therapies that can truly change the trajectory of this disease. Nylexa is unique in that it tackles both the infectious elements of COVID-19 and the body’s response to the SARS-CoV-2 virus. This could deliver significant and clinically meaningful benefit, particularly for the most vulnerable patients with secondary bacterial pneumonia. The impact of bacterial infections and antibiotic resistance in COVID-19 is beyond doubt. Our strategy to expedite Nylexa’s development to address this aligns 100% with the UK Government’s ‘wave 2 COVID-19 clinical trials’ strategy to test repurposed experimental therapies already in late stage clinical trials for other indications. Whilst ‘wave 1’ focused on the potential benefit of repurposed, already licensed antiviral and antimalarial therapies. Nylexa is low risk, low cost, readily available and scalable candidate treatment that could be tested and deployed to combat the coronavirus pandemic very quickly.”

Read more on the NovaBiotics website.

ONE LS Deborah O NeilDeborah O'Neil is CEO of Aberdeen-based drug discovery company NovaBiotics.
Stay up to date
Sign up to hear about Opportunity North East’s latest sector events and regional news.
By signing up to receive our newsletter, you accept our Privacy policy and Terms and Conditions. We will never share any of your personal data, and you can unsubscribe at any time.

Your privacy matters to us so if you want to find out more on how we keep your data safe, view our Privacy Notice or talk to ONE direct.

news
ONE industry hubs focal points for diversification
Jan 27 2023
BioHub to transform entrepreneurial growth in life sciences
Jan 27 2023
Agritech on my farm webinar
Jan 11 2023
twitterTweets by OpportunityNE_1
contact

Opportunity North East Ltd

11 Queens Gardens
Aberdeen
AB15 4YD

+44 (0)1224 061100

info@opportunitynortheast.com

  • About One
    Transforming our Region Annual Event 2022Transformational Leadership and ActionWho We AreDelivery and ImpactRegional EconomyONE Enterprise Fund
  • Transformational Projects
    BioHubSeedPodONE Tech HubSeafood Transformation ProjectNorth East Adventure TourismGourmet Food Festival
  • Digital Tech
    Transformational Leadership and ActionONE Tech HubAccelerate GrowthDigital CatalystInternationalisation and Market DevelopmentStrategic PartnershipsEnergyTechONE CodeBase Tech Startup Fundamentals
  • Energy
    Energy
  • Food, Drink & Agriculture
    Transformational Leadership and ActionSeedPodAccelerate GrowthTransform Food ProductionInternationalisation and Market DevelopmentStrategic Partnerships
  • Life Sciences
    Transformational Leadership and ActionBioHubAccelerate GrowthDigital CatalystInternationalisation and Market DevelopmentStrategic Partnerships
  • Tourism
    Transformational Leadership and ActionVisitAberdeenshireAccelerate GrowthGourmet Food FestivalNorth East Adventure Tourism
ONE (en-GB)
Privacy Policy | Terms and Conditions